Pulmatrix

Market position

Pulmatrix is a small-capitalization Nasdaq-listed biotechnology company; as of August 2026 its market capitalization was approximately $5.8 million with total cash of about $3.3 million and trailing twelve-month net income attributable to common shareholders of -$4.5 million. Yahoo Finance listed comparable small-cap biotechnology peers including Akari Therapeutics, Xenetic Biosciences, Bio-Path Holdings, ZyVersa Therapeutics, Artelo Biosciences and Tenax Therapeutics.

Pulmatrix differentiates on the iSPERSE particle-engineering approach, which the company says achieves dispersibility without lactose blending or low-density particles, permitting high drug loading delivery to the deep lung. For PUR1900, this is claimed to produce substantially higher lung and lower plasma exposure than oral itraconazole; for PUR3100, inhaled delivery is positioned against intranasal DHE administration.

Technology

iSPERSE is Pulmatrix's proprietary engineered dry powder inhalation technology based on small, dense, dispersible particles, avoiding the lactose blending or low-density particle approaches used by conventional dry powder formulations. It is intended to enable even dispersion of inhaled therapeutics throughout the lung and to deliver small or large molecule drugs for local or systemic use. Reported platform evidence includes PUR1900 (iSPERSE itraconazole) achieving roughly 50-fold higher lung exposure and 85-fold lower plasma exposure than oral Sporanox at one tenth the dose, and PUR3100 nonclinical dog pharmacokinetics showing rapid plasma exposure.

Go-to-market

Development-stage pipeline advanced through clinical trials, combined with partnering: PUR1900 is developed under a partnership with Cipla, described by Pulmatrix as India's second largest pharmaceutical company with presence in over 130 countries, more than 35 manufacturing facilities and a network for direct commercialization and strategic alliances. The company has stated it was exploring financing or partnership arrangements to initiate a potential Phase 2 study of PUR3100.

Patients with acute migraine, acute exacerbations of COPD, and allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis, reached through prescribers; pharmaceutical companies are targeted as licensing and co-development partners for the iSPERSE platform.

Geography

Headquartered in Massachusetts, United States, with contact addresses at 945 Concord Street, Suite 1217, Framingham, MA and 36 Crosby Drive, Suite 100, Bedford, MA. Development activity is described as focused on the United States; the PUR1900 partner Cipla is an India-based company with global presence.

History

MassDevice reported that Pulmatrix, then based in Lexington, Massachusetts, raised $3.5 million after emerging from stealth mode, in a financing tied to Polaris Ventures; the company was described as a Robert Langer-founded company, with Polaris managing partner Terry McGuire on its board. Yahoo Finance states the company was founded in 2003 and is headquartered in Framingham, Massachusetts. It became publicly traded on Nasdaq under the ticker PULM. In April 2022 Pulmatrix announced restoration of complete rights to its narrow-spectrum kinase inhibitor portfolio, including PUR1800, following termination of a licensing agreement with Johnson & Johnson's Enterprise Innovation. Anand Varadan was appointed to the board of directors effective July 26, 2021. In 2025-2026 the company pursued strategic alternatives: a divestment plan for its migraine and inhalation assets was announced with Q3 2025 results, a previously planned merger (with Cullgen) was terminated, and a merger agreement with Eos SENOLYTIX was announced.

Risks & controversies

Yahoo Finance data indicate financial and going-concern-type pressures: a market capitalization of about $5.8 million, negative enterprise value, total cash of $3.3 million, negative levered free cash flow of $3.7 million, return on equity of -84.3%, and share price declines of 65.6% over one year and 99.96% over the full listed history, with only 2 full-time employees. The company terminated a previously planned merger and announced plans to divest its migraine and inhalation assets, indicating pipeline discontinuation risk. Sources also conflict on basic facts: Yahoo Finance gives a 2003 founding date and Framingham headquarters, while LeadIQ lists Bedford, Massachusetts, 11-50 employees and approximately 16 employees, and the company website lists both Framingham and Bedford addresses.